MASA Life Science Ventures

MASA Life Science is a San Diego-based biotechnology company focused on developing novel therapeutics for metabolic diseases, including obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The company's lead program, MASA-101, is a potent and selective small molecule agonist of G protein-coupled receptor 120 (GPR120), also known as free fatty acid receptor 4 (FFAR4). By targeting GPR120, MASA Life Science aims to improve insulin sensitivity and reduce systemic inflammation, addressing the core drivers of metabolic dysfunction. The company leverages a virtual R&D model and maintains strong ties with academic researchers in the field of endocrinology and metabolism. MASA Life Science was founded by Masaaki Shiobara and is supported by a network of experienced advisors and investors in the life sciences sector.